228 related articles for article (PubMed ID: 25326864)
1. Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer.
Bertz S; Abeé C; Schwarz-Furlan S; Alfer J; Hofstädter F; Stoehr R; Hartmann A; Gaumann AK
Virchows Arch; 2014 Dec; 465(6):687-95. PubMed ID: 25326864
[TBL] [Abstract][Full Text] [Related]
2. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
[TBL] [Abstract][Full Text] [Related]
3. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
[TBL] [Abstract][Full Text] [Related]
4. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder.
Guancial EA; Werner L; Bellmunt J; Bamias A; Choueiri TK; Ross R; Schutz FA; Park RS; O'Brien RJ; Hirsch MS; Barletta JA; Berman DM; Lis R; Loda M; Stack EC; Garraway LA; Riester M; Michor F; Kantoff PW; Rosenberg JE
Cancer Med; 2014 Aug; 3(4):835-44. PubMed ID: 24846059
[TBL] [Abstract][Full Text] [Related]
5. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-inducible factor-1alpha expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma.
Chai CY; Chen WT; Hung WC; Kang WY; Huang YC; Su YC; Yang CH
J Clin Pathol; 2008 May; 61(5):658-64. PubMed ID: 17908805
[TBL] [Abstract][Full Text] [Related]
7. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
[TBL] [Abstract][Full Text] [Related]
8. Bromodomain 4 protein is a predictor of survival for urothelial carcinoma of bladder.
Yan Y; Yang FQ; Zhang HM; Li J; Li W; Wang GC; Che JP; Zheng JH; Liu M
Int J Clin Exp Pathol; 2014; 7(7):4231-8. PubMed ID: 25120803
[TBL] [Abstract][Full Text] [Related]
9. Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway.
Downes MR; Weening B; van Rhijn BW; Have CL; Treurniet KM; van der Kwast TH
Histopathology; 2017 Jan; 70(2):281-289. PubMed ID: 27530957
[TBL] [Abstract][Full Text] [Related]
10. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
van Oers JM; Zwarthoff EC; Rehman I; Azzouzi AR; Cussenot O; Meuth M; Hamdy FC; Catto JW
Eur Urol; 2009 Mar; 55(3):650-7. PubMed ID: 18584939
[TBL] [Abstract][Full Text] [Related]
11. Activation of extracellular regulated kinases (ERK1/2) predicts poor prognosis in urothelial bladder carcinoma and is not associated with B-Raf gene mutations.
Karlou M; Saetta AA; Korkolopoulou P; Levidou G; Papanastasiou P; Boltetsou E; Isaiadis D; Pavlopoulos P; Thymara I; Thomas-Tsagli E; Patsouris E
Pathology; 2009; 41(4):327-34. PubMed ID: 19404844
[TBL] [Abstract][Full Text] [Related]
12. CD147 overexpression allows an accurate discrimination of bladder cancer patients' prognosis.
Afonso J; Longatto-Filho A; Baltazar F; Sousa N; Costa FE; Morais A; Amaro T; Lopes C; Santos LL
Eur J Surg Oncol; 2011 Sep; 37(9):811-7. PubMed ID: 21733655
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder.
Liu JY; Li YH; Lin HX; Liao YJ; Mai SJ; Liu ZW; Zhang ZL; Jiang LJ; Zhang JX; Kung HF; Zeng YX; Zhou FJ; Xie D
BMC Cancer; 2013 Jul; 13():349. PubMed ID: 23870412
[TBL] [Abstract][Full Text] [Related]
15. Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations.
Hodgson A; van Rhijn BWG; Kim SS; Ding C; Saleeb R; Vesprini D; Liu SK; Yousef GM; van der Kwast TH; Xu B; Downes MR
Pathol Res Pract; 2020 Nov; 216(11):153186. PubMed ID: 32861170
[TBL] [Abstract][Full Text] [Related]
16. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
[TBL] [Abstract][Full Text] [Related]
17. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.
Burger M; van der Aa MN; van Oers JM; Brinkmann A; van der Kwast TH; Steyerberg EC; Stoehr R; Kirkels WJ; Denzinger S; Wild PJ; Wieland WF; Hofstaedter F; Hartmann A; Zwarthoff EC
Eur Urol; 2008 Oct; 54(4):835-43. PubMed ID: 18166262
[TBL] [Abstract][Full Text] [Related]
18. ARID1A alterations are associated with FGFR3-wild type, poor-prognosis, urothelial bladder tumors.
Balbás-Martínez C; Rodríguez-Pinilla M; Casanova A; Domínguez O; Pisano DG; Gómez G; Lloreta J; Lorente JA; Malats N; Real FX
PLoS One; 2013; 8(5):e62483. PubMed ID: 23650517
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.
Kim YS; Kim K; Kwon GY; Lee SJ; Park SH
BMC Urol; 2018 Jul; 18(1):68. PubMed ID: 30064409
[TBL] [Abstract][Full Text] [Related]
20. CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder cancer.
Xue YJ; Lu Q; Sun ZX
Med Oncol; 2011 Dec; 28(4):1363-72. PubMed ID: 20509007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]